| Literature DB >> 20512845 |
Kyle S McCommis1, Xiang He, Dana R Abendschein, Pradeep M Gupte, Robert J Gropler, Jie Zheng.
Abstract
A new (17)O-labeled blood contrast agent was injected intravenously in control dogs. Electrocardiogram (ECG)-triggered myocardial T(1)rho imaging was performed to obtain spin-locking T(1)rho-weighted myocardial signals for the detection of resultant metabolite H(2) (17)O water in the heart. Bolus and slow injection methods of various doses of the (17)O-labeled and (16)O-labeled agents were carried out in order to evaluate the sensitivity of this method and determine the optimal injection method. Bolus injection provided approximately 1% signal reduction, whereas slow injection with larger amount of agent yielded 11.9 +/- 0.6% signal reduction. Myocardial oxygen consumption rate was determined by a technique to quantify cerebral oxygenation consumption rate previously developed in (17)O brain studies. With either injection method, myocardial oxygen consumption rate at rest was 5.0 - 5.6 micromol/g/min. Therefore, it appears feasible to detect metabolically generated H(2) (17)O water in vivo in the heart, using the (17)O-labeled blood tracer. Myocardial oxygen consumption rate can then be quantified in vivo, which may open new doors for the assessment of myocardial metabolism. (c) 2010 Wiley-Liss, Inc.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20512845 PMCID: PMC2957225 DOI: 10.1002/mrm.22382
Source DB: PubMed Journal: Magn Reson Med ISSN: 0740-3194 Impact factor: 4.668